ERBB2 V842I

CI-VAR-00004646Explore in graph →NP_004439.2:p.Val842IleNM_004448.3:c.2524G>AClinVar 375994 CIViC 45 rs1057519738

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 6 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
ERBB2 V842I	Chemotherapy	Predictive	C	Supports Sensitivity Response	3	submitted	EID11501 Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID:CF0977). The patient was categorised as a “… (full text at CIViC) PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC	civic
Malignant Breast Neoplasm1
ERBB2 V842I	Neratinib	Predictive	D	Supports Sensitivity Response	5	accepted	EID289 In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375994	Uncertain significance	criteria provided, single submitter	1	Neoplasm; Colorectal cancer	germline/somatic	3	Oct 18, 2025	clinvar

Malignant Colon Neoplasm1
ERBB2 V842I	Lapatinib + Neratinib + TrastuzumabCombination	Predictive	D	Supports Sensitivity Response	4	accepted	EID1174 Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC	civic

Malignant Colorectal Neoplasm1
ERBB2 V842I	Cetuximab	Predictive	D	Supports Resistance	—	submitted	EID4520 bp]In an in vitro study, DiFi and NCI-H508 cell lines expressing an ERBB2 V842I mutation demonstrated resistance to cetuximab treatment, compared to DiFi and NCI-H508 cells expressing ERBB2 wild-type.… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC	civic

Pancreatic Ductal Adenocarcinoma2
ERBB2 V842I	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11561 HPNE cells infected with lentiviral vectors containing the variant did show significant phosphorylation of ERBB2 (Supplementary Figure 1) compared to WT (Figure 2A and B). The variant also exhibits an… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
ERBB2 V842I AND KRAS G12D	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11562 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic

Unmapped disease1unmapped disease
ERBB2 V842I	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID10025 A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC	civic